Infection News

Children who underwent fecal microbiota transplant, or FMT, experienced a significant reduction in recurrent Clostridioides difficile infection, or CDI, and a decrease in the prevalence of antimicrobial resistance genes in their gut microbiota, according to findings published in Open Forum Infectious Diseases.

Resistance-guided direct-acting antiviral retreatment resulted in nearly 90% sustained virologic response rates among patients with hepatitis C who developed resistance-associated substitutions after failing treatment with NS5A inhibitors.

Researchers discovered that an elevated fatty liver index was an independent risk factor for all-cause mortality in patients coinfected with hepatitis C and HIV, regardless of liver fibrosis or sustained virologic response to hepatitis therapy.

The FDA approved changes to the labeling of direct-acting antivirals Sovaldi and Harvoni to include information on dosage and administration in pediatric patients with hepatitis C aged 3 years to younger than 12 years.

Healio Gastroenterology and Liver Disease has compiled a list of some of the top stories we reported in August.

Because of the challenges associated with the reprocessing and cleaning of duodenoscopes with fixed endcaps, the FDA is recommending that manufacturers of the device and health care facilities transition to duodenoscopes with disposable components.

Janssen Pharmaceuticals initiated patient dosing in a phase 2b study of different regimens for the treatment of chronic hepatitis B including combinations of JNJ-3989, JNJ-6379 and nucleos(t)ide analog therapy, according to a press release from study collaborator, Arrowhead Pharmaceuticals.

The FDA has received reports that the use of Mavyret, Zepatier or Vosevi to treat chronic hepatitis C in patients with moderate to severe liver disease has resulted in rare cases of liver injury or liver failure, according to a drug safety communication.

Results from two independent cohorts revealed that patients who had negative test results for both hepatitis B DNA and hepatitis B RNA at the end of nucelos(t)ide analogue therapy were more likely to have continued response for 4 years or more.

The intrigue surrounding the use of fecal microbiota transplantation to treat various gastrointestinal disorders and infections has intensified over the last several years.